Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-17

Clinical Trial Update: Safety Study of F2695 SR in Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 safety study of F2695 SR in adults with Major depressive disorder has completed; the snippet does not include the trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • F2695 SR

Snippet

Sponsor: Forest Laboratories | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED